Transmission of drug-resistant HIV on the rise

July 06, 2002

A rising number of San Franciscans are being infected with HIV that is already resistant to some classes of antiretroviral drugs, report researchers from the Gladstone Institute of Virology and Immunology in the July 10th issue of the Journal of the American Medical Association.

The finding gives researchers clues about the effectiveness of anti-HIV drugs and underscores the need for new classes of drugs. In 2000-01, 27.4 percent of newly infected patients had virus that was resistant to at least one class of drugs, said lead author Robert Grant, MD, MPH, assistant investigator at Gladstone and UCSF assistant professor of medicine.

"That means about one in four are acquiring a virus with signs of drug-resistance," Grant said.

The study supports the use of drug resistance testing before starting antiretroviral therapy, especially in recently infected persons who were found to have high rates of drug resistance in this study.

"This is most true for patients located in places like San Francisco where anti-retroviral therapy is widely used," he said. Widespread use of antiretroviral drugs means that the virus passed on to a newly infected person is more likely to have developed resistance to one or more of those drugs.

The researchers studied 225 newly infected and untreated patients from June 1996 to June 2001. One way of testing for drug resistance against the three classes of drugs is to study the genetic sequence of the virus. This genotypic test reveals genetic mutations that cause drug resistance.

Most alarming was the increase in transmission of virus resistant to non-nucleoside reverse transcriptase inhibitors (nnRTIs). The nnRTIs are one of three major classes of anti-HIV drugs and are an important weapon in the arsenal against HIV. In 1996-97, none of the patients were infected with nnRTI-resistant virus, according to genotypic testing. In 2000-01, 13.2 percent were infected with nnRTI-resistant virus.

Transmission of virus resistant to protease inhibitors (PI) also increased. PIs are another class of drugs that have received much attention in the last several years for their potency. Infection with PI-resistant virus increased from 2.5 percent of patients in 1996-97 to 7.7 percent of patients in 2000-01.

"The efficacy of the two most potent classes of antiretroviral drugs is being offset by transmission of viruses resistant to them," Grant said.

Resistance can also be determined by phenotypic testing to assess the susceptibility of the virus to drugs in vitro. Virus that grows despite the presence of a drug is resistant to that drug, which means that it is less susceptible, but not impervious, to its effects.

Using phenotypic testing, the researchers found a dramatic decrease in the transmission of virus resistant to a third class of drugs called nucleoside reverse transcriptase inhibitors (nRTIs). AZT, the first drug ever to be used in the treatment of HIV infection, is a nRTI. In 1996-97, 20 percent of patients had nRTI-resistant virus. In 2000-01, only 5.5 percent had nRTI-resistant virus.

Phenotypic testing also showed that virus resistant to two classes of drugs was rare. However, genotypic testing showed an increase in the number of people infected with this type of dual-resistant virus, from 2.5 percent of patients in 1996-97 to 13.2 percent in 2000-01.

"This is an area where our data are not yet clear," Grant said. "The good news is that we only found one person out of more than 200 who was infected with a virus that was resistant to all three classes of drugs."

Another finding of the study: Drug resistance can be used to predict the time it takes for the drugs to control the virus. Resistant virus takes longer to control in patients who normally take a drug regimen that includes three or more drugs, the study showed.

In patients infected with drug-resistant virus, it took an average of 12 weeks for the antiretroviral drugs to suppress the viral load to below 500 copies/ml. In patients with drug-sensitive virus, it took only 5 weeks. Some viral suppression was possible in the majority of patients in both groups.

"Checking for drug resistance by looking at the genetic makeup of the virus predicts the time to viral suppression during therapy," Grant said. "However, viral suppression was eventually possible in the majority of patients because the transmitted resistance affected only some of the drugs in the regimen."

Dr. Grant added, "Although the risk of transmission of HIV-1 resistant to some types of therapy is increasing, the benefits of treatment include prolonging survival for the individual, and there may be benefits for the community as well, which were not directly assessed in our study. Our findings should not dissuade doctors from offering antiretroviral treatments. Rather, our study supports combining treatment with prevention interventions."
-end-
Co-authors also from Gladstone were Maria Warmerdam, BS, senior research associate, and Teri Liegler, PhD, staff research scientist. Co-authors from the Positive Health Program at San Francisco General Hospital Medical Center were Frederick M. Hecht, MD, UCSF professor of medicine, Lea Liu, MS, and James O. Kahn, MD, UCSF associate professor of medicine. Co-author Michael P. Busch, MD, PhD, is UCSF professor of laboratory medicine and director of research at the Blood Centers of the Pacific. Co-author Margaret Chesney, PhD, is co-director of the Center for AIDS Prevention Studies. Co-authors from ViroLogic--a biotech company that helped with phenotype testing and provided the assay for drug susceptibility--were Christos J. Petropoulos, PhD, vice president of research and development, and Nicholas S. Hellmann, MD, vice president for clinical research.

Funding for this study was provided by the Gladstone Institute of Virology and Immunology, the Centers for Disease Control and Prevention, the UCSF Center for AIDS Research, the University of California Universitywide AIDS Research Program, and the National Institutes of Health.

The Gladstone Institute of Virology and Immunology is one of three research institutes that comprise The J. David Gladstone Institutes, a private nonprofit biomedical research institution affiliated with UCSF. The institute is named for a prominent real estate developer who died in 1971. His will created a testamentary trust that reflects his long-standing interest in medical education and research.

University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.